

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Office of the Secretary****Findings of Research Misconduct****AGENCY:** Office of the Secretary, HHS.**ACTION:** Notice.

SUMMARY: Findings of research misconduct have been made on the part of Rajendra Kadam, former Ph.D. student in pharmaceutical sciences, University of Colorado, Denver (UCD) (Respondent). Mr. Kadam engaged in research misconduct in research supported by National Eye Institute (NEI), National Institutes of Health (NIH), grants R01 EY018940, R01 EY017533, R24 EY017045, and RC1 EY020361. The administrative actions, including debarment for a period of three (3) years, were implemented beginning on November 13, 2018, and are detailed below.

FOR FURTHER INFORMATION CONTACT:

Wanda K. Jones, Dr.P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Rajendra Kadam, University of Colorado, Denver: Based on an investigation conducted by UCD, the Respondent's admission, and analysis conducted by ORI in its oversight review, ORI found that Mr. Rajendra Kadam, former Ph.D. student in pharmaceutical sciences, UCD, engaged in research misconduct in research supported by NEI, NIH, grants R01 EY018940, R01 EY017533, R24 EY017045, and RC1 EY020361.

ORI found that Respondent engaged in research misconduct by knowingly and intentionally falsifying and/or fabricating data by manipulating LC-MS/MS peak area data to reduce variability and/or alter statistical significance for twenty-six (26) figures and five (5) tables in his Ph.D. thesis and in the following nine (9) published papers:

- *Drug Metab. Dispos.* 41:466–474, 2013 (hereafter referred to as “*Drug Metab. Dispos.* 2013”). Retracted in: *Drug Metab. Dispos.* 43(2):234, 2015 Feb.
- *Mol. Pharm.* 10:2350–2361, 2013 (hereafter referred to as “*Mol. Pharm.* 2013”). Retracted in: *Mol. Pharm.* 12(7):2559, 2015 July 6.
- *Invest. Ophthalmol. Vis. Sci.* 52(8):5387–99, 2011 (hereafter referred to as “*IOVS* 2011”). Retracted in: *Invest.*

Ophthalmol. Vis. Sci. 56(3):1678, 2015 Mar 9.

- *J. Control. Release* 172(3):1151–60, 2013 (hereafter referred to as “*J. Control. Release* 2013”). Retracted in: *J. Control. Release* 237:186, 2016 Sep 10.

- *Int. J. Pharm.* 434: 140–147, 2012 (hereafter referred to as “*Int. J. Pharm.* 2012”). Retracted (no date provided by the journal for the retraction notice).

- *Mol. Pharm.* 9:605–614, 2012 (hereafter referred to as “*Mol. Pharm.* 2012”). Retracted in: *Mol. Pharm.* 12(7): 2558, 2015 July 6.

- *J. Pharmacol. Exp. Ther.* 332:1107–1120, 2010 (hereafter referred to as “*J. Pharmacol. Exp. Ther.* 2010”). Retracted in: *J. Pharmacol. Exp. Ther.* 352(2):326, 2015 Feb.

- *Mol. Vis.* 19:1198–1210, 2013 (hereafter referred to as “*Mol. Vis.* 2013”).

- *Curr. Pharm. Biotechnol.* 12(2):285–292, 2011 (hereafter referred to as “*Curr. Pharm. Biotechnol.* 2011”). Erratum in: *Curr. Pharm. Biotechnol.* 17(9):846, 2016 Jun 6.¹

Specifically, Respondent falsified data included in:

- Figures 3.10 and 3.11 of respondent's thesis (also included as Figures 10 and 11 in *Drug Metab. Dispos.* 2013).
- Figures 5.2–5.7 of respondent's thesis.
- Figures 4.4–4.7 of respondent's thesis (also included as Figures 4–7 of *Mol. Pharm.* 2013).
- Figures 7.4, 7.5, and 7.7 of respondent's thesis (also included as Figures 1–5, 7, and 8 and summarized in Tables 2 and 3 of *IOVS* 2011).
- Figure 6 of *J. Control. Release* 2013.
- Figures 6–7 of *Mol. Vis.* 2013.
- Figure 3 in *Int. J. Pharm.* 2012.
- Figures 3 and 5–7 in *Mol. Pharm.* 2012.
- Figure 6C in *Curr. Pharm. Biotechnol.* 2011.
- Tables 3–5 and Figures 1–5 in *J. Pharmacol. Exp. Ther.* 2010.

Mr. Kadam entered into a Voluntary Exclusion Agreement (Agreement) and voluntarily agreed:

- (1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and

¹ While this publication does not cite U.S. Public Health Service (PHS) funding in its acknowledgements, Mr. Kadam was funded through his advisor's NIH funding while performing these experiments.

Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”) for a period of three (3) years beginning on November 13, 2018;

(2) to exclude himself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years beginning on November 13, 2018; and

(3) as a condition of the Agreement, to request that the following paper be retracted:

- *Mol. Vis.* 19:1198–1210, 2013.

Wanda K. Jones,*Interim Director, Office of Research Integrity.*

[FR Doc. 2018–26379 Filed 12–4–18; 8:45 am]

BILLING CODE 4150–31–P**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group Biobehavioral and Behavioral Sciences Subcommittee.

Date: February 11–12, 2019.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Bradley Monroe Cooke, 6710 B Rockledge Drive, Bethesda, Maryland 20892, 703.292.8460, brad.cooke@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: November 29, 2018.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018-26385 Filed 12-4-18; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Cancellation of Meeting

Notice is hereby given of the cancellation of the National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, December 6, 2018, 6:00 p.m. to December 7, 2018, 5:00 p.m., Residence Inn Arlington Pentagon City, 550 Army Navy Drive, Arlington, VA, 22202 which was published in the **Federal Register** on October 26, 2018, FR Doc. 23393.

This meeting has been cancelled and will be rescheduled.

Dated: November 29, 2018.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018-26386 Filed 12-4-18; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG-2018-0876]

Merchant Marine Personnel Advisory Committee; Vacancies

AGENCY: U.S. Coast Guard, Department of Homeland Security.

ACTION: Request for applications.

SUMMARY: The U.S. Coast Guard seeks applications for membership on the Merchant Marine Personnel Advisory Committee. This Committee acts solely in an advisory capacity to the Secretary of the Department of Homeland Security through the Commandant of the U.S. Coast Guard on matters relating to personnel in the United States merchant marine, including training, qualifications, certification, documentation, and fitness standards and other matters as assigned by the Commandant. The Committee advises, consults with, and makes recommendations reflecting its independent judgment to the Secretary and may make available to Congress

recommendations that the Committee makes to the Secretary. In addition, the committee may be given special assignments by the Secretary and may conduct studies, inquiries, workshops, and fact finding in consultation with individuals and groups in the private sector and with State or local governments.

DATES: Completed applications should be submitted to the U.S. Coast Guard on or before February 4, 2019.

ADDRESSES: Applicants should send a cover letter expressing interest in an appointment to the Merchant Marine Personnel Advisory Committee that identifies the applicant's preferred membership category along with a resume detailing the applicant's experience by one of the following methods:

- *By Email:* davis.j.breyer@uscg.mil, (preferred) Subjectline: The Merchant Marine Personnel Advisory Committee;
- *By Fax:* 202-372-8382 ATTN: Mr. Davis J. Breyer, Alternate Designated Federal Officer; or
- *By Mail:* Mr. Davis J. Breyer, Alternate Designated Federal Officer of the Merchant Marine Personnel Advisory Committee, Commandant (CG-MMC-1)/MERPAC, U.S. Coast Guard, 2703 Martin Luther King Jr. Ave SE, Stop 7509, Washington, DC 20593-7509.

FOR FURTHER INFORMATION CONTACT: Mr. Davis J. Breyer, Alternate Designated Federal Officer of the Merchant Marine Personnel Advisory Committee, Commandant, (CG-MMC-1)/MERPAC, U.S. Coast Guard, 2703 Martin Luther King Jr. Ave SE, Stop 7509, Washington, DC 20593-7509, telephone 202-372-1445, fax 202-372-8382 or davis.j.breyer@uscg.mil.

SUPPLEMENTARY INFORMATION: The Merchant Marine Personnel Advisory Committee is a federal advisory committee established in accordance with the provisions of the Federal Advisory Committee Act (Title 5 U.S.C. Appendix) and 46 U.S.C. 8108. The Committee meets at least twice each year. Its subcommittees and working groups may hold additional meetings as needed to consider specific tasks.

Each Committee member serves a term of office of up to three years. Members may serve a maximum of two consecutive terms. All members serve at their own expense and receive no salary or other compensation from the Federal Government. Members may be reimbursed for travel and per diem in accordance with Federal Travel Regulations.

The Committee meets at least twice each year. Its subcommittees and working groups may hold additional meetings as needed to consider specific tasks.

Each Committee member serves a term of office of up to three years. Members may serve a maximum of two consecutive terms. All members serve at their own expense and receive no salary or other compensation from the Federal Government. Members may be reimbursed for travel and per diem in accordance with Federal Travel Regulations.

We will consider applications for the following four positions that will be vacant on June 1, 2019. To be eligible, you must have the experience listed for the applicable membership position:

(1) One position for a member who serves as a representative of merchant marine engineering officers. To be eligible, you must be licensed as either a limited chief engineer or a designated duty engineer;

(2) One position for a member who serves as a representative of qualified members of the engine department. To be eligible, you must hold a current merchant mariner credential with an engineering rating endorsement;

(3) One position for a member who serves as a representative of shipping companies employed in ship operation management. To be eligible, you must show that you have significant knowledge and experience of shipping companies and ship operation management; and

(4) One position for a member who serves as a representative of the state maritime academies, as identified in 46 CFR 310 subpart A. To be eligible, you must be jointly recommended by such state maritime academies.

Each member will be appointed as Representative, and are not appointed in their individual capacity.

The Department of Homeland Security does not discriminate in the selection of Committee members on the basis of race, color, religion, sex, national origin, political affiliation, sexual orientation, gender identity, marital status, disabilities and genetic information, age, membership in an employee organization, or any other non-merit factor. The Department of Homeland Security strives to achieve a widely diverse candidate pool for all of its recruitment actions.

If you are interested in applying to become a member of the Committee, send your cover letter and resume to Mr. Davis J. Breyer, Alternate Designated Federal Officer of the Merchant Marine Personnel Advisory Committee via one of the transmittal methods in the **ADDRESSES** section by the deadline in the **DATES** section of this notice. All email submittals will receive email receipt confirmations.

Dated: November 29, 2018.

Jeffrey G. Lantz,

Director of Commercial Regulations and Standards.

[FR Doc. 2018-26420 Filed 12-4-18; 8:45 am]

BILLING CODE 9110-04-P